| Dr Brojo Sarkar, MD | |
|
1068 Cresthaven Rd, Suite 150, Memphis, TN 38119-0800 | |
| (901) 682-6828 | |
| Not Available |
| Full Name | Dr Brojo Sarkar |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 51 Years |
| Location | 1068 Cresthaven Rd, Memphis, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063437390 | NPI | - | NPPES |
| 107008001 | Other | AR | ARK MEDICAID |
| 0004364 | Other | TN | BLUE CROSS |
| 050049640 | Other | RR MEDICARE | |
| 000000122225 | Other | TN | BETTER HEALTH |
| 00010065 | Other | MS | MS MEDICAID |
| 2040386 | Other | TN | UNITED HEALTHCARE |
| 3181825 | Medicaid | TN | |
| 5986 | Other | TN | TLC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD11766 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital | Memphis, TN | Hospital |
| Saint Francis Bartlett Medical Center | Bartlett, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifelinc Anesthesia Ii, Pllc | 2668658493 | 115 |
News Archive
Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Scientists from Florida, USA, have conducted a study to determine the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from individuals with delta breakthrough infections. The findings reveal that delta breakthrough cases exhibit a relatively lower viral load compared to unvaccinated cases.
As families return from summer travels and children head back to school, Emergency Medical Associates (EMA) is preparing for a potential resurgence in the swine flu virus (H1N1) this fall. By using business intelligence (BI) solutions from SAP AG (NYSE: SAP), EMA will continue to pinpoint the movement of swine flu and alert federal organizations such as the Centers for Disease Control and Prevention (CDC) as well as 21 different emergency medical departments to patterns of outbreak.
› Verified 1 days ago
| Entity Name | East Memphis Anesthesia Services Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578592663 PECOS PAC ID: 1850386038 Enrollment ID: O20040416001400 |
News Archive
Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Scientists from Florida, USA, have conducted a study to determine the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from individuals with delta breakthrough infections. The findings reveal that delta breakthrough cases exhibit a relatively lower viral load compared to unvaccinated cases.
As families return from summer travels and children head back to school, Emergency Medical Associates (EMA) is preparing for a potential resurgence in the swine flu virus (H1N1) this fall. By using business intelligence (BI) solutions from SAP AG (NYSE: SAP), EMA will continue to pinpoint the movement of swine flu and alert federal organizations such as the Centers for Disease Control and Prevention (CDC) as well as 21 different emergency medical departments to patterns of outbreak.
› Verified 1 days ago
| Entity Name | Lifelinc Anesthesia Ii, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821397233 PECOS PAC ID: 2668658493 Enrollment ID: O20110512000311 |
News Archive
Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Scientists from Florida, USA, have conducted a study to determine the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from individuals with delta breakthrough infections. The findings reveal that delta breakthrough cases exhibit a relatively lower viral load compared to unvaccinated cases.
As families return from summer travels and children head back to school, Emergency Medical Associates (EMA) is preparing for a potential resurgence in the swine flu virus (H1N1) this fall. By using business intelligence (BI) solutions from SAP AG (NYSE: SAP), EMA will continue to pinpoint the movement of swine flu and alert federal organizations such as the Centers for Disease Control and Prevention (CDC) as well as 21 different emergency medical departments to patterns of outbreak.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brojo Sarkar, MD Po Box 171181, Memphis, TN 38187-1181 Ph: (901) 682-2872 | Dr Brojo Sarkar, MD 1068 Cresthaven Rd, Suite 150, Memphis, TN 38119-0800 Ph: (901) 682-6828 |
News Archive
Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.
Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
Scientists from Florida, USA, have conducted a study to determine the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from individuals with delta breakthrough infections. The findings reveal that delta breakthrough cases exhibit a relatively lower viral load compared to unvaccinated cases.
As families return from summer travels and children head back to school, Emergency Medical Associates (EMA) is preparing for a potential resurgence in the swine flu virus (H1N1) this fall. By using business intelligence (BI) solutions from SAP AG (NYSE: SAP), EMA will continue to pinpoint the movement of swine flu and alert federal organizations such as the Centers for Disease Control and Prevention (CDC) as well as 21 different emergency medical departments to patterns of outbreak.
› Verified 1 days ago
Dr. Joel R Slade, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1910 Nonconnah Blvd, Suite 120, Memphis, TN 38132 Phone: 901-448-2300 Fax: 901-448-6657 | |
Dr. Ruth Anne Bridges, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6005 Park Ave, Memphis, TN 38119 Phone: 901-682-2872 | |
Dr. Jeffrey A Blalack, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1265 Union Ave, Memphis, TN 38104 Phone: 316-685-6091 | |
Frederick D. Jones Iii, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5100 Poplar Ave Ste 2722, Memphis, TN 38137 Phone: 281-795-5891 | |
Dean M Harless, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 3362 S 3rd St, Memphis, TN 38109 Phone: 901-701-2510 | |
Meghan Vogt Burkley, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 50 N Dunlap St, Memphis, TN 38103 Phone: 901-287-6060 | |
Simindokht Hazrati, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 5744 Nanjack Cir, Memphis, TN 38115 Phone: 901-797-9711 Fax: 901-797-9771 |